Ved 54 uger var 44, 9% af patienterne i den kombinerede infliximabbehandlingsgruppe i klinisk respons sammenlignet med 19, 8% i placebobehandlingsgruppen (p < 0, 001).
At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response compared to 19.8% in the placebo treatment group (p < 0.001).